Navigation Links
Need For Low Cost, Heat Stable HIV Drug in Developing Countries

Medicins Sans Frontieres (MSF), an International humanitarian group has criticized the practice of marketing new or improved drugs in the developed countries and less adapted drugs in the Asian, African and Latin American countries //, where the need is more felt. More than 60, 000 patients in these regions benefit from the anti-retroviral treatment provided by the concern.

The drug known as ritonavir belongs to a class of compounds referred to as protease inhibitors. The latest version of the drug that is heat stable was launched for sale in the US in November 2005. The drug does not require refrigeration for storage, making it ideal for use in hot climates, prevalent in most developing countries.

The provision of new or improved versions of anti-retroviral drugs to HIV infected people in developing or poorly developed countries can make a huge difference. Despite this fact, a lot of people are denied access to such drugs on account of low affordability.

Although sub-Saharan Africa represents only about 10% of the world’s population, more than 60% of people in this region are afflicted with HIV/AIDS. The development of drug resistance to the first line of anti-retroviral poses a significant challenge to management of the AIDS epidemic in these regions. Such patients have to be provided with the drug lopinavir/ritonavir as a second line of treatment.

In line with the above situation, MSF would soon place an order for a heat stable form of the drug, lopinavir. Abbott Laboratories in Chicago currently markets the drug exclusively in the United States at an average wholesale price of 9,687 U.S. dollars.

'With the high temperatures and with the numerous daily electrical blackouts, our patients can't use the old version of this drug. It's a cruel irony that although this drug with no need for refrigeration seems to have been designed for places like Kenya, it is not available here,' said Dr. Christine Genevier, head of mission for MSF's AIDS treatment programs in Kenya.

'But when MSF inquired about the price and availability of this new product for its patients, Abbott responded that it would wait until the product was available in Europe before requesting marketing approval in developing countries. This means a potential delay of years before this drug reaches the people who can benefit from it most,'the MSF said.

Based on the evidence that the new heat stable formulation is associated with a reduced cost of production, the MSF has urged the US based pharmaceutical company to manufacture the drug and market the drug at an optimal price, not exceeding the amount charged for the older version in developing countries.

A letter drafted reflecting the concern of researchers, doctors and AIDS organizations from around the world has been forwarded to the CEO of Abbott Laboratories, urging the immediate supply of cost-effective ritonavir in developing countries.


'"/>




Related medicine news :

1. Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication
2. A.U. Health Ministers Receive Plan To Produce Low-Cost, Generic Drugs in Africa
3. Rahul Mahajans Condition Is Serious But Stable : Hospital
4. Togadiyas Condition Stable After Undergoing Angioplasty
5. Successfully Separated Conjoined Twins In A Critical Yet Stable Condition
6. Cancer Rates Falls In Younger Men But Stable In Young Women
7. Indonesian Siamese Twins With Three Legs In Stable Condition
8. Drugs Delivery Revolutionized by Extremely Stable Glass
9. Saif Ali Khan Recovering and Stable
10. Risk Of Developing Arthritis
11. Developing HIV fighter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: